Content Type: Article

  • State Law Privacy Video Series | Data of Minors

    State Law Privacy Video Series | Data of Minors

    ARTICLE / CLIENT ALERT / VIDEO

    State Law Privacy Video Series | Data of Minors

    April 13, 2022

    Read time: 3 min

    Overview

    California, Virginia and Colorado have new privacy laws coming into effect in 2023. But now is the time to start preparing your business or organization for compliance.

    In this video series, we examine the different aspects of these laws and provide you the knowledge and tools you need for proper compliance.

    In depth

    California, Virginia, Colorado, and now Utah, have new privacy laws coming into effect in 2023. However, now is the time to start preparing your business or organization for compliance.

    These state privacy laws provide important privacy protections for the data of minors. In particular, these laws contain several requirements for obtaining opt-in consent before selling or sharing the data of minors.

    In the video below, Associate Deepali Doddi explains how the various laws approach the privacy rights of minors.


    McDermott’s State Law Privacy Video Series: Data of Minors overview, 2022 (runtime: 3m42s)

    Conclusion
    More insights

  • FDIC Issues Letter on Crypto-Related Activities

    FDIC Issues Letter on Crypto-Related Activities

    ARTICLE / CLIENT ALERT

    FDIC Issues Letter on Crypto-Related Activities

    April 13, 2022

    Read time: 5 min

    Key takeaways
    Overview

    On April 7, 2022, the Federal Deposit Insurance Corporation (“FDIC”) released a Financial Institution Letter (the “Letter”)[1] in order to address FDIC-supervised institutions (“Covered Entities”) that are intending to engage or are already engaging in crypto-related activities.[2] The Letter requested that any Covered Entities seeking to engage in crypto-related activities notify the FDIC and provide all necessary information to the FDIC that would allow the agency to confer with the Covered Entity regarding related risks.[3] In addition, the FDIC requested prompt notifications from Covered Entities already conducting crypto-related activities.[4] The Letter also encouraged Covered Entities to notify their relevant state regulators, in addition to the FDIC.[5]

    Risks Posed by Crypto-Related Activities

    As support for the issuance of the Letter, the FDIC discussed the following safety and soundness, financial stability, and consumer protection risks that crypto-related activities pose.

    Safety and Soundness

    According to the Letter, safety and soundness concerns are implicated by the “new, heightened, or unique credit, liquidity, market, pricing, and operational risks” associated with crypto-related activities.[6] Examples included: (i) issues with validating and confirming ownership; (ii) anti-money laundering and countering terrorist financing implications due to “reported instances of crypto assets being used for illicit activities;” (iii) information technology and security risks; (iv) credit risk exposure linked to measuring, among other factors, asset quality and counterparty risk; (v) market risks due to pricing and valuation difficulties; and (vi) liquidity risk exposure given the volatility of crypto assets.[7]

    Financial Stability

    The Letter also asserted that crypto-related activities could pose systemic risks to the financial system. Systemic risks could result from the “interconnected nature of certain crypto-related activities” as well as through the structure of crypto assets.[8] The Letter pointed to the risk of “runs” on the financial assets which back crypto assets or crypto-related activities, creating a “self-reinforcing cycle of redemptions and fire sales of financial assets” which could cause market disruptions.[9] The FDIC also highlighted how operational failures involving crypto-related activities or crypto assets could destabilize Covered Entities engaging in crypto-related activities.

    Consumer Protection

    The FDIC expressed concerns about the risks that crypto-related activities could pose to consumers. In particular, the Letter emphasized that consumer confusion could occur regarding crypto-related services offered by Covered Entities. The FDIC also mentioned that Covered Entities could struggle in effectively applying consumer protection requirements (e.g., laws regarding unfair or deceptive acts or practices) to crypto-related activities.[10]

    Notifying the FDIC

    The Letter stated that Covered Entities should promptly notify the appropriate FDIC Regional Director prior to conducting, or if already conducting, crypto-related activity. This initial notice should describe the crypto-related activities in detail, along with the Covered Entities proposed timeline for conducting the crypto-related activities. The FDIC will then ask the Covered Entity to provide all information necessary to allow the FDIC to evaluate the safety and soundness, financial stability, and consumer protection risks associated with the crypto-related activity. After its review, the FDIC will provide feedback to the Covered Entity.

    Legal Implications

    In the Letter, the FDIC also highlighted that crypto-related activities can magnify risk to the Covered Entity, to consumers, and even to the Deposit Insurance Fund. As such, the FDIC expects Covered Entities to have the capacity to “demonstrate their ability to conduct crypto-related activities in a safe and sound manner.”[11]

    Schulte Roth & Zabel’s lawyers are available to assist you in addressing any questions you may have regarding these developments. Please contact the Schulte Roth & Zabel lawyer with whom you usually work or any of the following lawyers:

    Donald J. Mosher – New York (+1 212.756.2187)

    Melissa G.R. Goldstein – Washington, DC (+1 202.729.7471)

    Kara A. Kuchar – New York (+1 212.756.2734)

    Adam J. Barazani – New York (+1 212.756.2519)

    Jessica Romano – New York (+1 212.756.2205)

    Jessica Sklute – New York (+1 212.756.2180)

    Steven T. Cummings – New York (+1 212.756.2251)

    Hadas A. Jacobi – New York (+1 212.756.2055)

    Rebecca A. Raskind – New York (+1 212.756.2396)


    [1] FIL-16-2022: Notification and Supervisory Feedback Procedures for FDIC-Supervised Institutions Engaging in Crypto-Related Activities, FDIC (April 7, 2022) (the “Letter”), available here.

    [2] In the context of the Letter, the term “crypto-asset” generally referred to “any digital asset implemented using cryptographic techniques.” See id.  In addition, the term “crypto-related activities . . . includes acting as crypto-asset custodians; maintaining stablecoin reserves; issuing crypto and other digital assets; acting as market makers or exchange or redemption agents; participating in blockchain-and distributed ledger-based settlement or payment systems, including performing node functions; as well as related activities such as finder activities and lending.” See id. However, the Letter also noted that “given the changing nature of this area, other activities may emerge that fall within” the Letter’s scope. See id.

    [3] See id.

    [4] See id.

    [5] See id.

    [6] See id.

    [7] See id.

    [8] See id.

    [9] See id.

    [10] See id.

    [11] See id.


     This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2022 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Donald J. Mosher

    Partner

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Adam J. Barazani

    Partner

    New York – 919 Third Avenue

    More insights

  • HHS Announces Provider Relief Fund Late Reporting Pathway

    HHS Announces Provider Relief Fund Late Reporting Pathway

    ARTICLE / CLIENT ALERT

    HHS Announces Provider Relief Fund Late Reporting Pathway

    April 12, 2022

    Read time: 5 min

    Key takeaways
    Overview

    Beginning on April 11, 2022, providers that failed to satisfy Provider Relief Fund (PRF) Period 1 or Period 2 reporting deadlines may apply to submit a late report based on one of six extenuating circumstances, including miscommunication and illness. This announcement comes after the Health Resources and Services Administration (HRSA) notified thousands of recipients in March 2022 that they had to return non-compliant funds, which prompted the American Medical Association, Medical Group Management Association and other provider organizations to strongly urge additional reporting time in a March 31, 2022, letter to HRSA.

    In depth

    Provider Relief Fund Reporting Requirements
    Providers that received $10,000 or more in aggregated General and Targeted Distribution PRF payments must report on the use of funds in accordance with HRSA PRF reporting requirements. Providers that fail to satisfy reporting requirements may be excluded from receiving or retaining future PRF payments, including applicable Phase 4 payments. HRSA has also published a fact sheet regarding consequences of reporting noncompliance.

    The PRF Period 1 reporting deadline for funds received between April 10, 2020, and June 30, 2020, was September 30, 2021 (with a November 30, 2021, grace period). The Period 2 reporting deadline, related to funds received between July 1, 2020, and December 31, 2020, was March 31, 2022. Further details regarding the five PRF reporting periods, reporting deadlines and time periods in which recipients may use funds are outlined below. Notably, HRSA recently added a Period 5, which covers more recent distributions paid received from January 1, 2022, to June 30, 2022. Reports for Period 5 are due September 30, 2023.

    Payment Received Period
    (Payments Exceeding $10,000 in Aggregate Received)
    Period of Availability Reporting Time Period
    Period 1 April 10, 2020, to June 30, 2020 January 1,2020, to June 30, 2021 July 1, 2021, to September 30, 2021*
    Period 2 July 1 2020, to December 31, 2020 January 1, 2020, to December 31, 2021 January 1, 2022, to March 31, 2022
    Period 3 January 1, 2021, to June 30, 2021 January 1, 2020, to June 30, 2022 July 1, 2022, to September 30, 2022
    Period 4 July 1, 2021, to December 31, 2021 January 1, 2020, to December 31, 2022 January 1, 2023, to March 31, 2023
    Period 5 January 1, 2022, to June 30, 2022 January 1, 2020, to June 30, 2023 July 1, 2023, to September 30, 2023

    *Grace period ended on November 30, 2021.

    Request to Report Late Due to Extenuating Circumstances
    As announced, the agency will notify noncompliant providers with details regarding the late report application process after the applicable PRF reporting period closes. All requests are subject to HRSA approval and must be accompanied by an attestation regarding the occurrence of an allowable extenuating circumstance, outlined below.

    Applications to submit late reports for Period 1 must be submitted to HRSA by April 22, 2022, at 11:59 pm EDT. The submission deadline for late reporting requests for Period 2 has not been announced yet.

    Each request must be accompanied by an attestation and “clear and concise explanation” demonstrating that the provider experienced an allowable extenuating circumstance. While the application does not require the submission of supporting documentation, recipients should consider keeping a record of the explanation and supporting documentation along with the organization’s other PRF use, submission and compliance records.

    Allowable extenuating circumstances include the following:

    • Severe illness or death of the provider or key staff member responsible for reporting that hindered the timely report submission
    • Natural disaster occurring during or close to the reporting deadline that damaged records or information technology
    • Failure to receive reporting communications due to incorrect email or mailing address on file with HRSA that prevented the recipient from receiving reporting instructions prior to the deadline
    • Technical submission failure for organizations that registered and prepared reports, but did not take the necessary final step of clicking “submit”
    • Internal miscommunication or errors regarding the individual authorized or expected to submit a report for the recipient or the registered PRF point of contact in the portal
    • Incomplete Targeted Distribution report submissions if a parent organization completed all General Distribution reports, but a Targeted Distribution was not reported on by the subsidiary recipient

    Providers will have 10 days from the date the late report approval notice is received to submit a report in the PRF Reporting Portal. This timeframe is much shorter than the 60-day timeframe requested by the American Medical Association. Providers whose request is denied must return funds associated with reporting noncompliance. Recipients may not use the late reporting process to request an opportunity to make edits or adjustments to submitted reports. Providers that need assistance with revising submitted reports should contact the Provider Support Line at +1 866 569 3522.

    HRSA strongly encourages providers to complete their reports in the PRF Reporting Portal by the original deadlines outlined in the June 11, 2021, Post-Payment Notice of Reporting Requirements to ensure compliance with applicable terms and conditions.

    Upcoming Reports and Audits
    Period 3 PRF reports for funds received between January 1, 2021, and June 30, 2021, must be submitted by September 30, 2022. Many providers that have expended $750,000 or more in PRF monies may have audits covering prior reporting periods due around this time as well. For more information, see our OTS here and visit the HRSA Independent Audit Requirement Fact Sheet.

    Providers should be mindful that American Rescue Plan (ARP) Rural Fund payments are subject to slightly different requirements regarding use among related organizations, and recipients must certify under the ARP Rural Terms and Conditions that they will retain the payment with the provider(s) associated with the applicable subsidiary or billing TIN. The ARP Rural and PRF Phase 4 payments also require disclosure of certain mergers and acquisitions. For more information, see the HRSA Ownership Changes Fact Sheet.

    Additional details regarding PRF requirements and HRSA interpretative guidance is available on the HRSA PRF website, PRF Terms and Conditions website, and PRF FAQ pages.

    Authors
    More insights

  • Key Digital Asset Tax Proposals in the Biden Administration’s Green Book

    Key Digital Asset Tax Proposals in the Biden Administration’s Green Book

    ARTICLE / CLIENT ALERT / US POLICY

    Key Digital Asset Tax Proposals in the Biden Administration’s Green Book

    April 7, 2022

    Read time: 7 min

    Key takeaways
    Overview

    On March 28, 2022, the US Department of the Treasury released the Fiscal Year (FY) 2023 Revenue Proposals and Green Book, which describes the tax proposals in the Biden administration’s FY 2023 budget (2023 Budget Proposal). The 2023 Budget Proposal, if enacted in its current form, would expand the treatment of securities loans and mark-to-market tax accounting to include digital assets. It would also expand information reporting by certain financial institutions and brokers, as well as the reporting requirements for certain taxpayers who hold foreign digital assets. However, the Green Book does not include a definition of digital assets for these purposes. As a result, we expect that “digital assets” will have the same meaning as new Section 6045(g)(3)(D) of the Internal Revenue Code (Code) of 1986, as amended. This article summarizes the key 2023 Budget Proposals concerning digital assets.

    In depth

    DIGITAL ASSET LOANS

    Code Section 1058 generally provides that a taxpayer does not recognize gain or loss in connection with a loan of securities if certain requirements are met, including:

    1. The return to the transferor of securities identical to the securities transferred
    2. Certain payments made to the transferor of which the owner of the securities is entitled to receive during the course of the loan
    3. No reduction of the transferor’s risk of loss or opportunity for gain in the securities transferred.

    For this purpose, “securities” means corporate stock, notes, bonds, debentures and other evidence of indebtedness, and any evidence of an interest in, or right to, purchase any of the foregoing.

    The 2023 Budget Proposal would extend the nonrecognition of Code Section 1058 to loans of actively traded digital assets that are recorded on cryptographically secured distributed ledgers, provided that the loan has terms similar to those currently required for loans of securities as described above (e.g., any digital assets received by the borrower from airdrops or hard forks that occur during the course of the loan will be transferred to the lender). The US Secretary of the Treasury would have the authority to determine when a digital asset is actively traded, as well as the authority to extend the rules to non-actively traded digital assets.

    Adoption of this proposal would provide taxpayers with assurances that a transfer of digital assets pursuant to a properly structured Code Section 1058 loan agreement would not result in a taxable disposition.

    MARK-TO-MARKET TAX ACCOUNTING

    Code Section 475 requires dealers in securities to use the mark-to-market method of tax accounting for securities held at year end. Dealers in commodities and traders in securities or commodities may elect to use the mark-to-market method. Under current law, it’s unclear whether most digital assets would constitute a “commodity” for Code Section 475 purposes. As we have previously noted, Bitcoin and Ethereum are likely to be treated as commodities for these purposes because futures on these cryptocurrencies are traded on a commodities exchange. Additionally, because the tax definition of a commodity relies, in part, on how the Commodity Futures Trading Commission (CFTC) regulates cryptocurrencies and other digital assets, certain other cryptocurrencies and futures could be treated as commodities for tax purposes as well. (See “Can a Virtual Currency Position Be Treated as a Commodity for Tax Purposes?”) However, based on existing guidance, the tax treatment for such other cryptocurrencies and futures is less certain.

    The 2023 Budget Proposal would add actively traded digital assets, including derivatives on—or hedges of—actively traded digital assets, as an additional category of assets that are covered by Code Section 475. This would avoid the question of what a commodity under current law is. Again, the Treasury Secretary would have the authority to determine which digital assets are treated as actively traded, taking into account relevant facts and circumstances, which may include whether the digital asset is regularly bought and sold for US dollars or other fiat currencies, the volume of trading the digital asset on exchanges that have reliable valuations and the availability of reliable price quotations.

    While the 2023 Budget Proposal is silent as to whether certain digital assets might be considered as commodities under current law, it does state that digital assets are eligible for the mark-to-market election for Code Section 475 purposes only if such digital asset meets the requirements of an “actively traded digital asset.”

    DIGITAL ASSETS HELD OFFSHORE

    Under current law, Code Section 6038D requires individual taxpayers (and certain US entities) who hold an interest in one or more “specified foreign financial assets” with an aggregate value of at least $50,000 during a taxable year to attach a statement (currently provided on Internal Revenue Service (IRS) Form 8938, Statement of Specified Foreign Financial Asset) to the individual taxpayer’s federal income tax return. A “specified foreign financial asset” means (1) a financial account maintained by a foreign financial institution and (2) certain specified foreign assets not held in a financial account maintained by such a financial institution. In general, taxpayers are required to report the name and address of the financial institution where an account is maintained, the account number and identifying information about assets not held in a financial account. Failure to provide the required information for a taxable year can result in penalties.

    The 2023 Budget Proposal would expand the definition of “specified foreign financial assets” to include any account that holds digital assets maintained by a foreign digital asset exchange or other foreign digital asset service provider (foreign digital asset account). A foreign digital asset account would be based on where the exchange or service provider is organized or established.

    INFORMATION REPORTING

    Generally, any person doing business as a broker (i.e., a dealer, barter exchange or a person who, for a consideration, regularly acts as a middleman with respect to property or services) is required to report certain information about its customers to the IRS, such as the identity of each customer and the gross proceeds from sales of certain securities and commodities. Recently enacted Section 80603 of the Infrastructure Investment and Jobs Act of 2021 clarified that a broker includes any person who (for consideration) is responsible for regularly providing any service effectuating transfers of digital assets on behalf of another person. For this purpose, the term “digital asset” means any digital representation of value that is recorded on a cryptographically secured distributed ledger or any similar technology as specified by the Treasury Secretary.

    The 2023 Budget Proposal provides that brokers, such as US digital asset exchanges, would be required to report information relating to the substantial foreign owners of the passive entities that hold digital assets. By adopting such rules, brokers would be required to report gross proceeds and other information as the Treasury Secretary may require regarding the sale of digital assets with respect to customers and, in the case of certain passive entities, their substantial foreign owners.

    EFFECTIVE DATES

    In general, most of the proposals described herein take effect for taxable years beginning after December 31, 2022, except the rules relating to brokers, which would take effect for taxable years beginning after December 31, 2023.

    Authors

    John T. Lutz

    Partner

    New York – One Vanderbilt Avenue

    Andrew M. Granek

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • AdvaMed Updates Code to Provide Guidance on Innovative Arrangements, Medical Technology, Interactions with HCPs

    ARTICLE / CLIENT ALERT

    AdvaMed Updates Code to Provide Guidance on Innovative Arrangements, Medical Technology, Interactions with HCPs

    April 7, 2022

    Read time: 21 min

    Key takeaways
    Overview

    The Advanced Medical Technology Association (AdvaMed) announced its revised Code of Ethics on Interactions with Health Care Professionals (2022 Code) on March 18, 2022. Notable updates to the 2022 Code provide guidance on value-based care arrangements and address the integration of medical technology across products and services. Revisions also clarify requirements and best practices related to meetings, trainings, and communications with healthcare professionals (HCP). The revised 2022 Code will take effect on June 1, 2022.

    In depth

    The medical device industry has relied on the AdvaMed Code for decades to assist with navigating complex rules concerning compliance—particularly rules regarding fraud and abuse stemming from interactions with HCPs. AdvaMed’s latest revisions provide additional guidance on technologically enhanced delivery models and novel arrangements, such as those involving value-based care. The medical device industry is working to adjust its compliance programs to deal with the fact that the US Department of Health and Human Services Office of Inspector General (HHS-OIG) precluded medical device companies from taking advantage of the new value-based safe harbors, except in limited circumstances involving digital health technology. Innovative arrangements, such as those that advance value-based care, are changing the way technology is used and how HCPs interact with industry. The complex and evolving regulatory environment necessitated revisiting AdvaMed’s Code to provide additional guidance to industry. Other factors, including the integration of data analytics and an uptick in virtual events resulting from pandemic restrictions, add many layers of complexity to the already daunting task of establishing and maintaining a successful compliance program.

    Below, we provide a high-level overview of relevant updates and revised Frequently Asked Questions (FAQ) that are addressed in the 2022 Code.

    2022 Code Revisions

    Data-driven devices & solutions. AdvaMed added a new subsection to Section I in the 2022 Code to highlight the expanding role of data analytics and technology in the medical technology industry. The 2022 Code acknowledges that medical technology companies utilize data for many different purposes, including analyzing trends, delivering products and services, and improving quality of care and patient outcomes. This added subsection demonstrates that the 2022 Code contemplates integration of technological enhancements across products and services.

    Company-conducted programs and meetings; education and training for value-based care arrangements. Section III of the 2022 Code emphasizes that companies have a “legitimate need” to educate and train HCPs on how to incorporate and use their Medical Technologies, as defined by the 2022 Code. With the appropriate safeguards in place, meetings with HCPs to discuss value-based solutions, services or other arrangements may be permissible. Further, arrangements that “advance value-based care” may include product trainings and education activities presented by a particular company. Such trainings and educational activities may be associated with medical device(s) and related offerings (e.g., services, software, equipment or other similar offerings) that are, for example, designed to measure outcomes, as applicable.

    Consulting arrangements with HCPs. The 2022 Code expands on guidance relating to HCP consulting services to address HCPs assisting with the development, evaluation or implementation of value-based care arrangements. Consistent with the prior version of the 2022 Code, there should be a “legitimate need” for a consulting arrangement, it should be established in advance, and consultants should be selected carefully (e.g., through a vetting process) and paid fair market value for their services.

    Definitions: Updates and Additions

    The 2022 Code also adds and expands certain defined terms, including “Medical Technology,” “Value-Based Care,” and “Virtual.” These additions reflect the 2022 Code’s general modernization. While certain definitions are similar to terminology used in the Anti-Kickback Statute (AKS) Value-Based Enterprise (VBE) safe harbor provisions concerning digital health (see, e.g., 42 CFR § 1001.952(ee)(14)(ii), defining “Digital health technology”), the 2022 Code takes a broader approach. Because of this broader approach, it is important to remember that certain arrangements may still be permissible under a facts and circumstances analysis—even if criteria for a particular safe harbor are not met.

    • AdvaMed expanded the definition of “Medical Technology” in the 2022 Code. The term is generally defined to mean “medical devices and products, technologies, digital and software platforms, and related services, solutions, and therapies used to diagnose, treat, monitor, manage, and alleviate health conditions and disabilities. . . .”
    • The 2022 Code adds a new example to the definition: “[d]igital technology and software platforms that assist in . . . coordinating patient care.” This update is consistent with AdvaMed’s consideration of innovative tools used in the delivery of products and services.
    • The 2022 Code adds “Value-Based Care” as a defined term. The definition describes healthcare delivery models in which payment may be based on several factors, including patient health outcomes, population health outcomes, increasing access to healthcare for underserved populations, managing costs, and improving efficiency. Arrangements to advance value-based care are outcomes driven and “often condition payment or modify pricing for health care items or services based upon clinical, economic, and/or patient-experience outcomes, and may include payor-driven reimbursement arrangements for providers, arrangements between providers, and arrangements between providers and manufacturers or other participants in the health care system.”
    • “Virtual” means “an environment generally enabled by digital technology . . .” This newly defined term is consistent with AdvaMed’s effort to accommodate unique meeting formats in the 2022 Code revisions.

    Key Updates to Frequently Asked Questions

    Permissible Arrangements Under the Anti-Kickback Statute

    AdvaMed added a new FAQ to Section I (renumbered as FAQ #3) to address proposed arrangements that do not fit squarely within the AKS safe harbors (see 42 CFR § 1001.952). While certain arrangements may not meet all of the conditions of a potentially applicable AKS safe harbor, the 2022 Code emphasizes that a particular arrangement may still be permissible under a facts and circumstances analysis, which considers factors such as whether the arrangement would adversely impact access to care, whether clinical decision-making is compromised, and whether the arrangement would affect patient safety or quality of care. The intentions of those involved in an arrangement will also be considered as part of the facts and circumstances analysis.

    Interactions with HCPs Related to Value- or Outcomes-Based Care Arrangements

    AdvaMed added a new FAQ to Section I (renumbered as FAQ #4) to clarify that the 2022 Code applies to interactions with HCPs under arrangements that promote value- or outcomes-based care. The 2022 Code reiterates that certain value-based care arrangements may be permissible even if no safe harbor applies, consistent with OIG’s efforts to support “a broad range of participation and business structures.”

    Provision of Alcohol at Company-Conducted Programs and Meetings

    AdvaMed added a new FAQ to Section III (renumbered as FAQ #9) to provide guidance on the provision of alcohol at company-conducted meetings and programs. The guidance identifies potential controls to consider related the provision of alcohol, such as per-person drink limits, per-drink spending limitations, and restrictions on the type of alcohol served at the event (e.g., only beer and wine). The 2022 Code also highlights AdvaMed’s periodic benchmarking surveys (e.g., on best practices around providing modest meals and refreshments), which are available through its website for members.

    In HHS-OIG’s November 16, 2020 Special Fraud Alert addressing speaker programs, HHS-OIG considered the provision of alcohol a “suspect characteristic.” In the 2022 Code, AdvaMed seeks assist industry with developing safeguards to ensure offerings are less likely to raise concerns. AdvaMed’s approach is less stringent than the revised PhRMA Code’s guidance, which advises against the provision of alcohol altogether (see our prior discussion of the revised PhRMA Code here).

    Provision of Modest Meals or Refreshments to HCPs

    AdvaMed’s 2022 Code outlines best practices concerning the provision of modest meals to HCPs in Section VII. Generally, companies may provide HCPs with meals and refreshments, but they must be modest and “subordinate in time and in focus” to the purpose of the meeting. The 2022 Code includes further clarification through the addition of two new FAQs:

    • A new FAQ in Section III (renumbered as FAQ #10) underscores that companies should consider factors set forth in Section VI when determining an appropriate venue for holding a company-conducted meeting at a restaurant. Factors include determining whether there is a legitimate need or reason for holding a meeting at a particular venue and if the location is appropriate for the exchange of information, among other considerations. Certain practices, such as paying for guests to attend, are not permitted.
    • A new FAQ in Section VII (renumbered as FAQ #29) provides clarification concerning the provision of meals and refreshments when programs are held virtually. The 2022 Code recommends establishing controls and processes to ensure proper ordering and delivery. Procedures should involve tracking attendance to ensure that the intended recipients (i.e., attendees) receive meals or refreshments. Generally, home delivery is not permitted.

    Communication of Economic Efficiency Information Relating to Medical Technology

    A new FAQ was added to Section XI (renumbered as FAQ #34) to clarify that it is permissible to provide certain accurate and objective information about the economically efficient use of Medical Technology as long as the information sharing does not result in unlawful inducement or impact an HCP’s clinical decision-making. While consistent with prior AdvaMed guidance, this updated FAQ clarifies that a company may provide coverage, reimbursement, and health economics information to an HCP for the purpose of developing or negotiating a value- or outcomes-based contract.

    Key Takeaways

    Medical technology companies and HCPs should consider whether the 2022 Code warrants changes to their compliance policies and procedures. The delayed effective date allows industry time to review current practices and align with relevant updates. The 2022 Code provides helpful guideposts but does not override laws, regulations, or other governing codes that may be in effect. Stakeholders should keep this in mind as they consider their particular arrangements in light of the recent 2022 Code revisions.

    Code Section AvaMed Code 2009 AvaMed Code 2020 AvaMed Code 2022
    Section I – Introduction I. Preamble: Goal and Scope of AdvaMed Code and II. Code of Ethics Compliance

    Definitions:

    • Medical Technologies: medical products, technologies, and related services and therapies used to diagnose, treat, monitor, manage and alleviate health conditions and disabilities
    • Health Care Professionals (HCPs): individuals or entities involved in the provision of health care services and/or items to patients, which purchase, lease, recommend, use, arrange for the purchase or lease of, or prescribe Companies’ Medical Technologies in the United States.
    Consolidates former sections I and II into a new Section I – Introduction section.

    New “Cornerstone Values”: Innovation, Education, Integrity, Respect, Responsibility & Transparency

    New Definitions: Commercial Sponsorship, Educational Grant, Satellite Symposium, Third-Party Program, Third-Party Program Organizer

    Revised Definitions:

    • Medical Technologies: medical devices and products, technologies, digital and software platforms, and related services, solutions and therapies used to diagnose, treat, monitor, manage and alleviate health conditions and disabilities (e.g., implantable medical devices; surgical devices; digital technology and software platforms; and non-invasive reagents, instrumentation or software).
    • HCPs: any person or entity (a) authorized or licensed in the United States to provide health care services or items to patients or (b) who is involved in the decision to purchase, prescribe, order or recommend a Medical Technology in the United States. This term includes individual clinicians (for example, physicians, nurses and pharmacists, among others), provider entities (for example, hospitals and ambulatory surgical centers) and administrative personnel at provider entities (for example, hospital purchasing agents). Does not include Health Care Professionals who are bona fide employees of a Company, while acting in that capacity.
    New “Data-Driven Devices & Solutions” information:
    acknowledges the role that technology and data-driven solutions play in industry, as well as the potential for improved outcomes and quality of care.Revises the recommendation to submit an annual certification to AdvaMed declaring compliance with the Code; “a certification” is now sufficient.

    New FAQ (FAQ #3 in 2022 Code): underscores that proposed interactions that do not fit within the AKS safe harbors may be permissible under a facts and circumstances analysis.

    New FAQ (FAQ #4 in 2022 Code): reiterates that the 2022 Code applies to communications with HCPs under arrangements that involve value- or outcomes-based care.

    Adds & revises definitions:

    • Medical Technology (revised): “Medical Technology is a broad term that means medical devices and products, technologies, digital and software platforms, and related services, solutions, and therapies used to diagnose, treat, monitor, manage, and alleviate health conditions and disabilities. Some examples include:
      . . . Digital technology and software platforms that assist in monitoring, diagnosing, and treating patients or in coordinating patient care . . .”
    • Virtual (added): “An interaction that involves attendees participating in a virtual environment that is generally enabled by digital technology rather than meeting in a physical location.”
    • Value-Based Care (added): “A health care delivery model in which contributors to care are paid based on individual patient health outcomes, population health outcomes, increasing access to healthcare for underserved populations, managing costs, and/or improving efficiency.”Arrangements to advance value-based care (also referred to as results-based, outcomes-based, or performance-based payment arrangements) are designed to increase shared accountability among stakeholders for quality of, access to, and/or the total cost of care. These arrangements often condition payment or modify pricing for health care items or services based upon clinical, economic, and/or patient-experience outcomes, and may include payor-driven reimbursement arrangements for providers, arrangements between providers, and arrangements between providers and manufacturers or other participants in the health care system.”
    Section II – Consulting Arrangements with Health Care Professionals VI. Consulting Arrangements with Health Care Professionals

    “Consulting arrangements should be entered into only where a legitimate need for the services is identified in advance and documented.”

    “Compensation paid to a consultant should be consistent with fair market value in an arm’s length transaction for the services provided and should not be based on the volume or value of the consultant’s past, present or anticipated business . . . There are different valuation methods that may be used to establish fair market value. In all instances, a Company should use objective, verifiable criteria. The method or methods used by
    a Company should be documented.”

    Moves to Section II – Consulting Arrangements with Health Care Professionals.

    Clarifies that a “legitimate need arises when a company requires the services of a HCP to achieve a specific objective, such as the need to train HCPs on the technical components of safely and effectively using a product; the need for clinical expertise in conducting product research and development; or the need for a physician’s expert judgment on clinical issues associated with a product.”

    Explains how to develop fair market value (FMV) methodology: many third-party vendors or other experts can assist a company in developing an approach to assessing FMV compensation. In all instances, a company should use a method that incorporates objective criteria (e.g., an HCP’s specialty, years and type of experience, geographic location, practice setting, the type of services performed).

    States that sales personnel must not control or unduly influence the decision to engage an HCP as a consultant, because separation is necessary to avoid the perception that a company has entered into a contract with an HCP to secure or reward the HCP for purchasing, using or recommending the company’s medical technology or other sales considerations.

    Also notes that HCPs’ interactions with companies may create potential conflicts of interests (COIs) (e.g., through leadership roles in medical societies, conference planning, medical journal editorial staff). Companies should be aware of these potential COIs and mindful of steps that may be necessary to address conflicts, such as recusal from decisions that implicate conflict.

    In addition to entering into consulting arrangements for an HCP’s services in advance, companies should confirm that services are performed in accordance with the agreement.

    Revises “Key Concepts”: relating to engaging an HCP for consulting services. The 2022 Code clarifies that engaging an HCP for consulting services may include “assisting in the development, evaluation, or implementation of an arrangement to advance value-based care.”
    Section III – Company-Conducted Programs & Meetings with Health Care Professionals III. Company-Conducted Product Training and Education; V. Sales, Promotion, and Other Business Meetings Consolidates former sections III and V into a new Section III – Company-Conducted Programs & Meetings with Health Care Professionals to cover all company-conducted programs. Revisions clarify that:

    • Companies have a responsibility to train HCPs on how medical technologies may improve value-based care arrangements.
    • Arrangements to “advance value-based care” may include product trainings and education activities presented by a company. Such training and education may be related to medical device(s) and equipment designed to measure outcomes, as applicable (e.g., services, software, and other equipment or similar offerings).
    • Companies may meet with HCPs to discuss value-based solutions, services or arrangements.
    • Virtual meetings serve as an appropriate setting.

    New FAQ (FAQ #9 in 2022 Code): to provide additional clarity on the provision of alcohol at company meetings and programs; revisions present options to limit availability to attendees.

    New FAQ (FAQ #10 in 2022 Code): factors set forth in Section VI should be considered when determining an appropriate venue for holding a company-conducted meeting at a restaurant.

    Section IV – Educational & Research Grants, Charitable Donations, and Commercial Sponsorships IV. Supporting Third-Party Educational Conferences; XI. Research and Educational Grants and Charitable Donations

    Research Grants: “Company may provide research grants to support independent medical research with scientific merit. Such activities should have well-defined objectives and milestones and may not be linked directly or indirectly to the purchase of Medical Technologies.”

    Charitable Donations: Donations should be motivated by bona fide charitable purposes and should be made only to bona fide charitable organizations or, in rare instances, to individuals engaged in genuine charitable activities for the support of a bonafide charitable mission.

    Consolidates former sections IV and XI into a new Section IV – Educational & Research Grants, Charitable Donations, and Commercial Sponsorships.

    Educational Grants: Focuses definition on payment or in-kind support to a third-party entity (e.g., Third-Party Program Organizer or training institution) and clarifies that these programs may or may not be accredited to provide continuing education credits. Also clarifies that third parties may only use grant funds to provide items permissible under the Code. Adds a checklist for grant “Review Processes” for use in evaluating grant requests.

    Commercial Sponsorship: Clarifies that company sponsors may not pass along any benefits they receive from the third-party organizer (e.g., complimentary conference registrations) to an HCP.

    Satellite Symposia: Companies may cover expenses for an HCP to serve as a bona fide faculty member, including at a Satellite Symposium (limited, as appropriate, to the time necessary to speak at the Satellite Symposium). Companies may not cover expenses if the HCP is merely attending the Symposium.

    Research Grants: Clarifies requirements for supporting independent research grant requests:

    • Objectives & Milestones: defined goals, objectives and milestones; accompanied by clinical protocols; document the nature and scope of the research activity, the budget, the approximate duration of research, and requirements for independent authorizations or approvals (e.g., FDA approval).
    • Limitation: in-kind or monetary support for legitimate, study-related, documented expenses or services, or reasonable quantities of no-charge product for limited duration of research.
    • Company Involvement: recipient should retain independent control over research.
    • Company Review Process: company should establish controls for reviewing requests for research grants.
    • Sales Involvement: sales personnel should not control or unduly influence the decision of who will receive support or the amount of support.

    Charitable Donations: Clarifies requirements for providing charitable donations:

    • Charitable or Philanthropic Mission: for bona fide charitable purposes and only to charitable organizations and non-profits with bona fide charitable or philanthropic purposes. Companies should consider the entity’s tax status, corporate status under state law, and whether the organization has a charitable mission or purpose, among other factors.
    • Use of Funds: company must require donations be used only toward charitable or philanthropic purposes.
    • Indigent Care Donations: company may make donations of product for indigent patients, but these donations must serve exclusively to the benefit of patients and be otherwise permitted under applicable laws (e.g., state law). Companies should consider including a provision that no third parties will be billed for the donated product in a formal agreement with a hospital.
    • Charitable Events: companies may not pay for HCPs to attend charitable events.
    • Sales Involvement: sales personnel should not control or unduly influence the decision whether a particular entity will receive support or the amount of support.
    No notable substantive changes.
    Section V – Jointly Conducted Education and Marketing Programs New Section V – Jointly Conducted Education and Marketing Programs

    Companies may partner with HCPs to conduct joint education and marketing programs designed to highlight Medical Technology and an HCP’s ability to diagnose or treat medical conditions if:

    • There is a bona fide, legitimate need to engage in the activity for its own educational or marketing benefit.
    • The company establishes controls to help ensure decisions to engage in these arrangements are not made as an unlawful inducement.
    • Content is balanced between the company and the HCP.
    • The company and the HCP make equitable contributions toward the activity and cost.
    • The arrangement is documented in a written agreement that describes the purpose, roles, responsibilities and contributions of each party.
    No notable substantive changes.
    Section VI – Travel & Lodging; Venue III. Company-Conducted Product Training and Education; IV. Supporting Third-Party Educational Conferences; V. Sales, Promotional, and Other Business Meetings; VI. Consulting Arrangements with Health Care Professionals Consolidates existing travel and venue guidance into new Section VI – Travel & Lodging; Venue.

    Travel:

    Permitted:

    • To provide consulting services to a company, if the HCP is subject to an executed consulting agreement and there is an objective, legitimate reason to support in-person participation
    • To attend company-conducted training or education program concerning Medical Technologies and there is an objective, legitimate reason to support in-person attendance
    • To speak on the company’s behalf at Third-Party Program
    • Other programs or meetings if there is an objective, legitimate reason that supports in-person attendance

    Not permitted for general education programs.

    Venue: Provides additional guidance on evaluating appropriate venues for meetings, including:

    • Central location and ease of accessibility (such as proximity to airports or highways)
    • Not selected because of entertainment or recreational facilities (e.g., season or time of year)
    • Avoid top category or luxury hotels or resort facilities without appropriate justification
    Revisions clarify that:

    • While companies may pay for modest and reasonable travel and lodging, there are limitations and guiderails. There must be a “legitimate need” for travel, and the revised 2022 Code encourages companies to consider whether a legitimate need may be met via a virtual program or meeting.
    • Certain principles apply to the chosen setting (e.g., must be conducive to information exchange); however, the principles set out in the 2022 Code apply when the meeting is in person (as they relate to physical settings).
    Section VII – Providing Modest Meals and Refreshments to Health Care Professionals III. Company-Conducted Product Training and Education; IV. Supporting Third-Party Educational Conferences; V. Sales, Promotional, and Other Business Meetings; VI. Consulting Arrangements with Health Care Professionals; VIII. Modest Meals Associated with Health Care Professional Business Interactions Consolidates guidance on meals and replaces section VIII with new Section VII – Providing Modest Meals and Refreshments to Health Care Professionals.

    Strongly encourages companies to develop policies on providing modest and occasional meals to HCPs, including establishing a per-meal spending limit and with consideration for geographic variances.

    New FAQ (FAQ #29 in 2022 Code): to provide guidance concerning the provision of meals or refreshments when programs are held virtually. The 2022 Code recommends establishing controls and processes to ensure proper ordering and delivery.
    Section VIII – Educational & Patient Benefit Items; Prohibition on Gifts IX. Educational Items; Prohibition on Gifts No significant revisions. No notable substantive changes.
    Section IX – Prohibition on Entertainment & Recreation VII. Prohibition on Entertainment and Recreation Moved to Section IX – Prohibition on Entertainment & Recreation. Revisions emphasize that “[e]ntertainment and recreational activities are inconsistent with the appropriate business purpose of a Company’s interactions with Health Care Professionals.”
    Section X – Communicating for the Safe & Effective Use of Medical Technology New Section X – Communicating for the Safe & Effective Use of Medical Technology.

    Contains principles for communicating unapproved or uncleared (off-label) uses:

    • Only by authorized personnel (e.g., in response to unsolicited requests and by medical affairs)
    • Truthful and non-misleading
    • Identified as off-label

    Companies are encouraged to develop policies and controls that incorporate FDA guidance, judicial decisions, and other relevant applicable authorities.

    No notable substantive changes.
    Section XI – Provision of Health Economics & Reimbursement Information X. Provision of Coverage, Reimbursement and Health Economics Information Moved to Section XI – Provision of Health Economics & Reimbursement Information.

    No significant revisions.

    New FAQ (FAQ #34 in 2022 Code) and revisions to permissible activities: clarifies that it is permissible to provide certain accurate and objective information (e.g., reimbursement, economic efficiency information) when a company negotiates with an HCP to develop or negotiate a value- or outcomes-based contract in accordance with the conditions set forth in the 2022 Code.
    Section XII – Demonstration, Evaluation, and Consigned Products XII. Demonstration & Evaluation Products Enhances existing language with clarity on when it is acceptable to provide evaluation products and contents of evaluation agreement; adds language that companies should be mindful of transparency requirements; adds language on consignment products and recommendations for controls. No notable substantive changes.
    Section XIII – Company Representatives Providing Technical Support in the Clinical Setting New Section XIII – Company Representatives Providing Technical Support in the Clinical Setting.

    Provides principles for company representatives providing technical support in the clinical setting, for example:

    • Direction/supervision of HCP to explain how a Medical Technology’s settings and technical controls function
    • Assisting in clinical/operating room to ensure the appropriate range of necessary devices and accessories are available during a procedure, especially when the Medical Technology involves multiple devices or accessories

    Company personnel:

    • Should only enter and be present in clinical setting at request and supervision of HCP
    • Should be transparent that they are acting on behalf of the company in a technical support capacity
    • Should not interfere with an HCP’s independent clinical decision-making
    • Should comply with applicable hospital or facility policies and requirements (e.g., patient privacy, credentialing requirements).
    • A company’s technical support should not eliminate an overhead or other expense that the HCP should otherwise incur while providing patient care.
    AdvaMed offerings and descriptions of resources removed.
    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    James A. Cannatti III

    Partner

    Washington, DC

    More insights

  • State Law Privacy Video Series | Contracting

    State Law Privacy Video Series | Contracting

    ARTICLE / CLIENT ALERT / VIDEO

    State Law Privacy Video Series | Contracting

    April 6, 2022

    Read time: 3 min

    Overview

    California, Virginia and Colorado have new privacy laws coming into effect in 2023. But now is the time to start preparing your business or organization for compliance.

    In this video series, we examine the different aspects of these laws and provide you the knowledge and tools you need for proper compliance.

    In depth

    Most businesses are familiar with privacy contracts, sometimes called data protection addenda (DPAs), which govern the sharing of personal data in the context of B2B services. However, the new privacy laws will expand both the terms that have to be included in these contracts as well as the circumstances in which these contracts are required.

    In the video below, Associate Austin Mooney explains these requirements, which businesses this applies to and what you need to do now.


    McDermott’s State Law Privacy Video Series: Contracting overview, 2022 (runtime: 3m14s)

    Conclusion
    More insights

  • HPE Miami 2022 The Healthcare Investment Banker’s Perspective—The New Normal

    HPE Miami 2022 The Healthcare Investment Banker’s Perspective—The New Normal

    ARTICLE

    HPE Miami 2022 The Healthcare Investment Banker’s Perspective—The New Normal

    April 6, 2022

    Read time: 5 min

    Key takeaways
    Overview

    Leading investment bankers discussed the current market climate for healthcare investing coming out of the record-setting pace in 2021. They also shared their insights on hot sectors, growth strategies and the dealmaking outlook for 2022 and beyond. Fred Levenson, Partner & Co-Head of McDermott’s Private Equity Partner, hosted the panel, with insights from:

    • Michael Dodds, Managing Director, Jefferies & Company
    • Mark Francis, Managing Director, Head of Healthcare, Houlihan Lokey
    • Simon Gisby, Principal, Life Sciences & Health Care Leader, Deloitte Corporate Finance
    • Philip Pucciarelli, Partner, Perella Weinberg Partners
    • Wyatt Ritchie, Managing Director, Cain Brothers
    In depth

    Top takeaways from the panel included:

    1. All five panelists made it abundantly clear: in today’s fast-paced dealmaking landscape, the player who walks in with the work done upfront will walk away with a deal in hand. “When you make the first call be ready to run,” Simon Gisby said. Deals are happening faster than ever, especially with the convenience afforded by Zoom. Startups should invest upfront in consulting and strategy before starting any processes. Everyone involved in the dealmaking process should do as much work as possible upfront to show your organization’s seriousness and to prevent unnecessary roadblocks from cluttering your path to a deal.

    2. Another point that all five panelists stressed is that healthcare will continue to be a strong sector moving forward. Everyone had a rosy outlook. Panelists pointed to the fact that even non-healthcare funds are looking to healthcare as a smart investment. The wealth curve has left many well-capitalized investors considering healthcare investments including family offices, companies like Google and private investors like Jeff Bezos. That’s a wide array of players in the field and so much interest is expected to keep things moving quickly and keep valuations elevated.

    3. Large companies like Google and Amazon are investing in the healthcare space and their commitments will likely grow. Their involvement has contributed to creating a landscape where there is more venture capital rushing to invest in the sector than there are startups, allowing new companies to emerge at a fast rate. Entrepreneur investors are also chasing healthcare. However, many startups could be looking at coming into the space as disruptors, impacting investments in traditional healthcare providers. Ultimately, a wide array of players could create challenges. “There’s just a significant amount of capital chasing too few assets,” Philip Pucciarelli said.

    4. Investors with ready capital are thick on the ground and will continue to be in the foreseeable future. “There is an endless supply of dry powder,” Michael Dodds said. Investors are getting creative and it will be interesting to see if megadeals continue. There will be plenty of money flowing in from myriad sources including buyout money, conveners, Amazon Care and other investors, creating an interesting confluence of capital. This atmosphere looks set to hold through 2022.

    5. “There may be a day of reckoning coming in the next few years,” Wyatt Ritchie said. If the debt markets crack, valuations could come down. Rising interest rates and the ripple effect of the conflict in Ukraine could also impact valuation and dealmaking. Inflation is the biggest risk as it will increase expense ratios and that can impact valuations. However, none of these factors is expected to have a devastating impact, and the private equity market isn’t likely to see a sea change.

    6. The landscape has changed for prospective buyers with the emergence of a wave of European investors on the scene. With insufficient deal flow in Europe, many funds are incentivized to deploy more capital in the US than in Europe. The fact that partners in the US are paid on a US waterfall instead of a European waterfall is a factor that creates incentives to do more and bigger deals in the US. The way that European players make deals could also influence the dealmaking landscaping, changing processes.

    7. “Ask yourself, how do you buy time, how do you save time in a process?” Mark Francis posed, in order to emphasize where everyone’s focus should be going into first- and second-round negotiations. CEOs and CFOs cannot sit any part out and must make time to get the pulse of PE investors, understand what family offices think of their space and seek feedback with consultants. This gives their companies an edge. Doing the legwork in early cycles, maintaining strong interpersonal and intercompany relationships, and having your ducks in a row before you start any process is the path to victory.

    Authors
    More insights

  • HPE Miami 2022 PE Fundraising 3.0: Continuation Vehicles, Single-Asset Funds and Secondaries

    HPE Miami 2022 PE Fundraising 3.0: Continuation Vehicles, Single-Asset Funds and Secondaries

    ARTICLE

    HPE Miami 2022 PE Fundraising 3.0: Continuation Vehicles, Single-Asset Funds and Secondaries

    April 6, 2022

    Read time: 5 min

    Key takeaways
    Overview

    In this session, Ian Schwartz, Partner and Head of McDermott’s Investment Funds Practice, moderated a discussion that explored fundraising strategies and transaction structures that optimize liquidity and long-term returns from private equity funds’ strongest assets. Session panelists included:

    • Rob Campbell, Managing Director, Co-Head of Americas, Intermediate Capital Group
    • Tim Fitzsimmons, Managing Director, Lorient Capital
    • Garrett Hall, Managing Director, Secondary Investments, AlpInvest Partners
    • Ryan Rohloff, Senior Managing Director, Evercore
    In depth

    Top takeaways from the panel included:

    1. To help ensure that the audience was speaking the same language, Ryan Rohloff offered a brief description and overview of continuation funds and why they have become so popular in recent years. “A continuation fund, effectively, is a better mousetrap than doing a fund-of-funds sale or selling one of your best companies to another sponsor. You take an asset of any vintage and move it into a continuation fund that typically has a new lease on life from a duration perspective, follow-on capital, etc.” Rohloff also noted that continuation funds have been around for several decades, but for much of that time continuation funds were only applicable to sponsors as their funds reached 10 years old or were going into extensions. 2021 was the first year in which more than half of the continuation deals, or half of the overall market, were transacted out of funds that were six years old or younger.

    2. Rob Campbell described the types of deals that his company is looking for, where they can act as the secondary player, and what they are looking for in terms of alignment with the general partner (GP): “We are very focused on alignment. We want to see evidence that the GP is a buyer alongside of us in the asset.” He also described what they don’t want to see: They are not pursuing transactions where the GP tested the M&A market and failed, and therefore pivoted to a continuation vehicle. On the other hand, the list of favorable elements that Campbell’s team looks for include a great management team in place, strong organic growth within the asset, and M&A serving as a catalyst (in the sense that the asset may have outgrown the size for portfolio construction within the flagship fund, they don’t have the dry powder to support that asset, or they’re out of their investment period).

    3. Tim Fitzsimmons provided the GP/sponsor’s perspective on reasons to pursue a continuation fund rather than a traditional sale. Noting that his company operates in a smaller end of the market, he said that his company takes a two-fold approach to making the decision to pursue a continuation fund: “We look at it at the company level and at the portfolio, or fund, level.” As examples, Fitzsimmons mentioned multi-site healthcare services, clinical businesses focused on value-based care, and others, always with a view toward realigning investors for the next stage of growth and development of the company. He emphasized the importance of being clear about expectations for the next stage (e.g., duration or term of the investment opportunity, new exit strategy).

    4. Ian Schwartz suggested that a continuation fund can help strengthen existing relationships between private equity sponsors and portfolio company management teams. Fitzsimmons concurred, saying “Many of these bubble up from the management team dynamic; they’re good assets and really good management teams, and as everyone knows, management teams are a leading indicator of the success of an investment.” A continuation fund allows that relationship and bond to continue. Rohloff noted that, from a process perspective, many of these transactions are relatively frictionless for management and allow them to continue executing on the plan. “These transactions allow you to provide management liquidity, reload them with a new management incentive plan, and really realign all constituents on the new cost basis, without having them go through the exercise that they would with a traditional exit.”

    5. Garrett Hall pointed out a distinction between the continuation fund and M&A processes, noting that his firm spends a lot of time speaking with GPs in order to get a sense of the quality of the business so they can de-risk the process and build collaboration. Campbell underscored the importance of frank, early discussions so that investors can be pointed to appropriate opportunities and transactions that satisfied all players. Hall reiterated that multi-asset deals are much easier to negotiate and close than single-asset deals, and that secondary market demand is much deeper for the former—therefore, you should think more holistically and package multiple deals together, rather than pursuing a series of one-offs.

    6. Fitzsimmons noted that healthcare has always been a specialist strategy and must respond to unique regulatory and other dynamics. That said, he added that the market is jam-packed, including new funds, spinouts, re-ups and more, so limited partners (LPs) are feeling strained right now. The public markets are likely to have an effect on fundraising and capital availability, and many LPs are waiting to see how things play out. Hall suggested that people open their minds to the new ways that capital is raised today (blindfold capital, secondary capital, etc.) and that these methods operate on different cycles. Continuation fund opportunities are worth exploring and, as Schwartz concluded, the area is only going to grow.

    Authors

    Ian M. Schwartz

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • HPE Miami 2022 Financing Healthcare Deals

    HPE Miami 2022 Financing Healthcare Deals

    ARTICLE

    HPE Miami 2022 Financing Healthcare Deals

    April 6, 2022

    Read time: 6 min

    Key takeaways
    Overview

    In this session, Stephanie McCann, Partner and Co-Head of McDermott’s Finance Practice, led a wide-ranging discussion of critical strategies for investors to consider as they seek sources of capital to finance healthcare deals. Session panelists included:

    • Javier Casillas, Chief Credit Officer & Managing Director, WhiteHorse Finance
    • Matthew Evans, Managing Director, Head of Healthcare Finance, Monroe Capital
    • Scott Gallin, Partner, Linden Capital Partners
    • Aman Malik, Managing Director, HPS Investment Partners
    • Bryan Rupprecht, Managing Director & Head of Healthcare, MidCap Financial
    In depth

    Top takeaways from the panel included:

    1. Although 2021 was not without its issues, the first quarter of 2022 has already provided a long list of challenges for healthcare markets: geopolitical uncertainty (including US and global sanctions on Russia), rising interest rates, increasing prices for energy and other goods and services, ongoing COVID disruptions and the LIBOR transition, to name just a few. Despite the expected bumps, Scott Gallin noted that his company is “absolutely expecting 2022 to be as busy as the last couple of years have been.” With many companies coming to market, Gallin noted, “we are fortunate that healthcare, despite all these macro-pressures, is still pretty resilient.” He added, “We just have to incorporate those macro-vectors into our models to ensure that we are doing sound underwriting.”

    2. The energy industry may seem distinct from the healthcare industry, but, said Aman Malik, rising fuel prices will have an impact on certain activities such as home healthcare services. “Reimbursement doesn’t flex up immediately,” he noted, it is typically set at the start of the year. Regarding inflation, Malik said “If you have interest rates go up by a point and you have growth slow down a little bit, you’re going to be in a world where interest payments and everything could be [an issue].” On the subject of rising wages, Bryan Rupprecht said, “I would emphasize that there are certain subsectors—say, skilled nursing homes—where the model literally is not going to work. Wages are such a high percentage of the total costs that, when the pandemic is over and they stop getting the increased payments from the government and they have this new cost structure, every nursing home in the country is bankrupt.”

    3. Stephanie McCann noted a number of issues underwriters must consider, including timing and diligence, loan to value (i.e., purchase price), sponsor-backed versus non-sponsor-backed options, sector/industry differentiation, and asked the panelists for their thoughts. From an investment committee perspective, Javier Casillas said, “Aside from obvious credit criteria, we are focused the enterprise value of the firm and its resilience and sustainability.” Rupprecht added, “What’s unique to today, relative to history, is the COVID bump stuff. Every company that we invest in that’s doing super well, the management teams and the equity firms are saying that ‘this is the new normal,’” while the companies that are not doing well, “say ‘This is a COVID hit and we’re going to bounce back as soon as COVID is over.’”

    4. McCann posed a question about EBITDA adjustments and company valuation and wondered if the panelists gave any consideration to whether the company is sponsor-backed or non-sponsor-backed, and whether there was any leniency for sponsor-backed companies. Casillas pointed out that there is now a third category: independent sponsors. “We find that to be a very fruitful and interesting place to play. You have a lot of institutional sponsors that have spun off funds that have very smart and experienced people who are buying companies, and there’s good business there and there are good fits—we are very actively in that market.” Matthew Evans noted that, “At the end of the day, if you have the majority of your underwritten EBITDAs in adjustment, there still needs to be cash flow at some point.” He said that his firm is looking “at 13-week cash flows at a close to make sure we’re going to have cash to service the debt.”

    5. When asked about a growing tendency for lenders to go “capless,” Rupprecht noted that a large majority of deals have no covenants. “These companies are going to run out of money before they trip a covenant,” he said, “that’s just the straight-up reality. What we try to do is keep the revolvers small, because a) they’re extremely expensive for us, and b) when you run out of money, we don’t want you to go hit a $40 million revolver and just keep bleeding this company for the next two years because I know you’re not going to trip the covenant.”

    6. At the mid-cap level, said Rupprecht, regulatory enforcement and qui tam issues have traditionally been a major concern, but that this was not unique to the healthcare environment. The big challenge today, he said, is “trying to figure out what is the new normal.” He mentioned telehealth as something that is here to stay, but added that this wasn’t true of all companies that experienced revenue growth during the pandemic. Gallin elaborated on the new normal and questioned whether some of the changes in consumer behavior are a result of the pandemic only, or because of better marketing or information sharing. Evans noted that underwriting processes have accelerated and that deals are being negotiated very quickly—a compression of timeframes that makes it very difficult to conduct appropriate due diligence, and an issue that doesn’t appear to be going away very soon.

    Authors

    Stephanie S. McCann

    Partner

    Chicago

    More insights

  • HPE Miami 2022 Healthcare Services Investing: Disruption and Dispersion

    HPE Miami 2022 Healthcare Services Investing: Disruption and Dispersion

    ARTICLE

    HPE Miami 2022 Healthcare Services Investing: Disruption and Dispersion

    April 6, 2022

    Read time: 4 min

    Key takeaways
    Overview

    The kick-off session of HPE Miami 2022 focused on the latest trends causing the most disruption in healthcare investing and forecasted what the healthcare investing landscape could look like moving forward. Ira Coleman, McDermott Partner & Chair, moderated the panel featuring insights from:

    • Alex Albert, Founding Partner, Patient Square Capital
    • Alex Carles, Managing Partner & Co-President, Wellspring Capital Management
    • Paige Daly, Partner, Harvest Partners
    • Jeremy Gelber, Senior Managing Director, Centerbridge Partners
    • Curtis Lane, Founder, WindRose Health Investors & Founding Partner, MTS Health Partners
    In depth

    Top takeaways from the panel included:

    1. Burnout, staffing shortages and inflation are creating continued pressure. The threat of employees leaving the workforce should be a top-of-mind concern for investors, Alex Carles noted. “We’ve never seen a greater need for really sophisticated human resources performance to both recruit talented individuals and also to manage through this compression.”

    2. Private equity sponsors are uniquely positioned to offer support and leadership around talent management issues. “During the pandemic, a lot of us built up some muscles around employee support networks, really trying to think about ways that we could make sure that we were building companies that people were excited to say they worked at and that they were proud of,” Paige Daly said. “One of the things that we think about a lot on the private equity side is how we can use our lens looking across companies to share capabilities, strengths and innovations.”

    3. Participating in companies that are making a meaningful difference in patients’ lives is increasingly important. “There’s an incredible war for talent, and at every level we’re seeing not just challenges with compensation, but a real demand to be part of something that’s having an impact,” Alex Albert said. “As private equity healthcare investors, we do this because we think we can improve patient lives.” The adoption of remote work arrangements during the COVID-19 pandemic has facilitated this focus on impact,” he said. Five years ago, having a management team located in different offices might have signaled instability, but today’s more flexible work arrangements can help gather the best talent available with a strong focus on mission.

    4. The robust pace of healthcare investing activity seems set to continue through 2022, even amid current geopolitical uncertainty. “The good news for us is that healthcare is always there and it is always changing,” Curtis Lane said. “There are always transactions to do—to build out a portfolio company, to add to a portfolio, to sell out a portfolio. That’s always going to be there, particularly with the amount of capital that’s behind the industry.” While appetite for transactions remains strong, there is some question regarding pricing trends, Lane said. The market has shifted in the past three to six months, Daly agreed, resulting in a greater emphasis on business model fundamentals and likely a reversion to more traditional ways of valuing businesses. “That’s a big change that’s going to create business model shakeout and opportunities on the investment side,” she said.

    5. As healthcare services companies consider going public, management teams must be realistic about the related operating challenges. Many healthcare companies that went public between 2019 and 2021 haven’t performed as well as expected, Jeremy Gelber said. “A lot of them just didn’t remember that you actually have to be able to forecast your business in a granular or quarterly way, and hit your numbers or exceed your numbers,” he said. “That takes a lot of infrastructure and it takes the right, predictable business model.” A management team may be highly talented and producing well, but operating effectively as a public company requires an additional core skillset.

    Authors

    Ira J. Coleman

    Chairman

    Miami

    More insights